-
Mashup Score: 1
AbstractAims. The aim of this study was to evaluate the efficacy and safety of prasugrel dose de-escalation therapy in patients with diabetes mellitus (DM)–acut
Source: academic.oup.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 10Comparison of bleeding risk between standard ticagrelor and prasugrel therapies without de-escalation strategy - 9 month(s) ago
This commentary refers to ‘Dual antiplatelet therapy de-escalation in acute coronary syndrome: an individual patient meta-analysis’ by J. Kang et al., 2023, htt
Source: academic.oup.comCategories: Cardiologists, Latest HeadlinesTweet-
Comparison of bleeding risk between standard ticagrelor and prasugrel therapies without de-escalation strategy. Read more in EHJ. https://t.co/mrgcxDY6Rj @escardio @ESC_Journals # #BleedingRisk #Ticagrelor #Prasugrel #EHJ https://t.co/TsAnv6KmaL
-
-
Mashup Score: 34Ticagrelor vs Prasugrel in a Contemporary Real-World Cohort Undergoing Percutaneous Coronary Intervention: - 1 year(s) ago
Abstract Background Potent P2Y12 agents such as ticagrelor and prasugrel are increasingly utilized across the clinical spectrum of patients undergoing percutaneous coronary intervention (PCI). Ther…
Categories: Expert Picks, Latest HeadlinesTweet-
In this contemporary patient population undergoing #PCI, #prasugrel and #ticagrelor were associated with similar 1-year efficacy and safety. https://t.co/2wjG8VPz6Q #JACCINT #cvACS #CardioTwitter @DrAnoop_Koshy @g_giustinoMD @Drroxmehran https://t.co/neSunw5P2j
-
-
Mashup Score: 2Body mass index and efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndromes - PubMed - 2 year(s) ago
NCT01944800.
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet-
#BMI and efficacy and safety of #ticagrelor versus #prasugrel #ACS #DAPT https://t.co/PFMoVhr3IB
-
-
Mashup Score: 2Influence of body size on platelet response to ticagrelor and prasugrel in patients with acute coronary syndromes - PubMed - 2 year(s) ago
Influence of body size on platelet response to ticagrelor and prasugrel in patients with acute coronary syndromes
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet-
Influence of #BodySize on platelet response to #ticagrelor and #prasugrel in patients with acute coronary syndromes https://t.co/c3G1wUs8rT
-
-
Mashup Score: 0
This post hoc analysis investigates whether the benefits of prasugrel dose de-escalation therapy are maintained in the complex percutaneous coronary intervention subgroup.
Source: jamanetwork.comCategories: Cardiologists, Latest HeadlinesTweet-
HOST-REDUCE-POLYTECH-ACS: a dose-reduction in #prasugrel to 5mg/d at 1mo post-PCI decreased risk of bleeding but did not incr the risk of ischemic events up to 1yr after noncomplex #PCI;it is unknown if results are similar for pts undergoing complex PCI. https://t.co/BWODwpIegX
-
-
Mashup Score: 1
This post hoc analysis investigates whether the benefits of prasugrel dose de-escalation therapy are maintained in the complex percutaneous coronary intervention subgroup.
Source: jamanetwork.comCategories: Cardiologists, Latest HeadlinesTweet-
#Prasugrel Dose De-escalation Therapy After Complex PCI in Patients With #ACS A Post Hoc Analysis From the HOST-REDUCE-POLYTECH-ACS Trial Prasugrel dose de-escalation was not associated with an increased risk of ischemic outcomes https://t.co/Clo25fbPZI @JAMA_current @JAMACardio https://t.co/X5FOQNtOU7
-
-
Mashup Score: 24Meta-Analysis Comparing the Safety and Efficacy of Prasugrel and Ticagrelor in Acute Coronary Syndrome - 2 year(s) ago
Prasugrel and ticagrelor are preferred over clopidogrel for patients with acute coronary syndrome who underwent percutaneous coronary intervention. We sought to determine the relative merits of 1 agent over the other. Multiple databases were queried to identify relevant randomized control trials (RCTs) and observational cohort studies. Random-effects model was used to calculate an unadjusted odds…
Source: American Journal of CardiologyCategories: Cardiologists, Latest HeadlinesTweet-
RT @SABOURETCardio: #MetaAnalysis Comparing the #Prasugrel and #Ticagrelor in #ACS - American Journal of Cardiology https://t.co/NLPa9NfR76
-
-
Mashup Score: 10Comparison of Prasugrel and Ticagrelor for Patients with Acute Coronary Syndrome: A Systematic Review and Meta-analysis - PubMed - 2 year(s) ago
Of the 11 eligible RCTs with 6098 patients randomized to prasugrel (n=3050) or ticagrelor (n=3048), 180 and 207 had the composite endpoint events in the prasugrel arm and the ticagrelor arm respectively over a weighted mean follow up period of 11±2 months. Compared with prasugrel, the ticagrelor gro …
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet-
Comparison of #Prasugrel and #Ticagrelor for Patients with Acute Coronary Syndrome: A Systematic Review and Meta-analysis - only the ESC guidelines have a preferred #P2Y12i based on 1 OPEN RCT @AngoulvantD @DocSavageTJU #DAPT #EBM https://t.co/cnnc6FFK1r
-
-
Mashup Score: 3NSTE-ACS ESC Guidelines Recommend Prasugrel as the Preferred P2Y12 Inhibitor: A Contrarian View - 2 year(s) ago
In the 2020 European Society of Cardiology guidelines on non-ST-segment elevation acute coronary syndromes (NSTE-ACS), the experts proposed to put an end to the equipoise of ticagrelor and prasugrel in addition to aspirin in patients with NSTE-ACS who …
Source: PubMed Central (PMC)Categories: Cardiologists, Latest HeadlinesTweet-
NSTE-ACS ESC Guidelines Recommend #Prasugrel as the Preferred P2Y12 Inhibitor: A Contrarian View #DAPT . First published article to challenge the #ESCGuidelines kind reminder…🤔 https://t.co/vmVz20WFPy
-
Is #DAPT for 12 months the optimal strategy ? #Prasugrel dose de-escalation in diabetic patients with #ACS #PCI HOST-REDUCE-POLYTECH-ACS trial https://t.co/SW2bejPbgy